REG-argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026
argenx presented new long-term data for efgartigimod in myositis and Sjogren’s disease at the EULAR 2026 Congress, showing sustained clinical benefit and consistent safety. In the ALKIVIA+ myositis study, 37.5% of patients on continuous treatment maintained major improvement at 52 weeks, with comparable results for those switching from placebo. In the RHO+ Sjogren’s study, patients switching to biweekly dosing maintained response, with median disease activity scores remaining low (2.5 and 2.0) at week 72.
Key figures
- Drug Name
- efgartigimod
- Phase Of Trial
- Phase 2
- Myositis mean tis switch
- 49.62
- Myositis mean tis continuous
- 52.19
- Cross indication patient years
- 1,300+
- Cross indication treated patients
- 834
- Sjogrens median clinessdai switch
- 2
- Myositis major tis improvement switch
- 33.3%
- Sjogrens median clinessdai efgartigimod
- 2.5
- Myositis moderate tis improvement switch
- 66.7%
- Myositis major tis improvement continuous
- 37.5%
- Myositis moderate tis improvement continuous
- 75.0%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.